Daito Pharmaceutical Co.,Ltd.
Simbols: 4577.T
JPX
2540
JPYTirgus cena šodien
12.0844
P/E koeficients
-0.4769
PEG koeficients
39.73B
MRK Cap
- 0.02%
DIV ienesīgums
Daito Pharmaceutical Co.,Ltd. (4577-T) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3607 | 4381 | 3372.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | -205 | -206 | -294.2 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 10670 | 10585 | 8382 | |||||||||||||||
balance-sheet.row.inventory | 0 | 18238 | 16820 | 15751.7 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 8148 | 6123 | 4923.3 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 40663 | 37909 | 32429.9 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 25837 | 23116 | 21372 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 377 | 386 | 332.7 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 377 | 386 | 332.7 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 3169 | 2958 | 3096 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 504 | 570 | 508 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | -1 | 0.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 29887 | 27029 | 25309.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 1 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 70552 | 64939 | 57739.4 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 4435 | 4493 | 4359.6 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1513 | 1200 | 1375.1 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 559 | 1402 | 1098.5 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 3445 | 2247 | 2018.9 | |||||||||||||||
Deferred Revenue Non Current | 0 | 507 | 755 | 764.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 4101 | 3887 | 3399.9 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 4153 | 3199 | 2963.2 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 92 | 0 | 1.5 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 19581 | 17268 | 15822 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 49141 | 46273 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 7186 | 7031 | 6271.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 35006 | 32338 | 28331.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1531 | 1031 | 872.4 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -42192 | -39369 | 6143.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 50672 | 47304 | 41619 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 70552 | 64939 | 57739.4 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 299 | 367 | 298.4 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 50971 | 47671 | 41917.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 2964 | 2752 | 2801.8 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4958 | 3447 | 3394 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1351 | -934 | 21.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 5076 | 6720 | 5873.9 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 3870 | 3313 | 3154.3 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -2326 | -4399 | -1582.4 | |||||||||||||||
cash-flows.row.account-receivables | 0 | -1502 | -3299 | 2723 | |||||||||||||||
cash-flows.row.inventory | 0 | -1413 | -1041 | -3609.2 | |||||||||||||||
cash-flows.row.account-payables | 0 | 538 | 22 | -765.1 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 51 | -81 | 69 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -2465 | -1264 | -2263.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -5556 | -4733 | -6349.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 68 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -68 | 0 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 256 | 5 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | -10 | 77 | 20.3 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -5566 | -4400 | -6324.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -1638 | -1444 | -1712.4 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 308 | 1514 | 1798.5 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -116 | 1499 | -0.3 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -931 | -660 | -658.1 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2993 | 80 | 1997 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 616 | 989 | 1424.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 20 | 48 | 5.8 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -774 | 1009 | 288.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3607 | 4381 | 3372.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 4381 | 3372 | 3084.1 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 4155 | 4370 | 5182.5 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -5556 | -4733 | -6349.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | -1401 | -363 | -1167 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 45101 | 43464 | 48709.2 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 34770 | 32005 | 37917.3 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 10331 | 11459 | 10791.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 3 | 37 | 28.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 5123 | 4905 | 4883.1 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 39893 | 36910 | 42800.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 45 | 46 | 0.4 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 12 | 9 | 7.8 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -135 | 152 | -43 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 3 | 37 | 28.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -135 | 152 | -43 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 12 | 9 | 7.8 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3870 | 3313 | 3154.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 5207 | 6553 | 5908.8 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 5076 | 6720 | 5873.9 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 1549 | 2092 | 1716.9 | |||||||||||||||
income-statement-row.row.net-income | 0 | 3600 | 4668 | 4246 |
Biežāk uzdotie jautājumi
Kas ir Daito Pharmaceutical Co.,Ltd. (4577.T) kopējie aktīvi?
Daito Pharmaceutical Co.,Ltd. (4577.T) kopējie aktīvi ir 70552000000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.214.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 346.005.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.073.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.093.
Kāda ir Daito Pharmaceutical Co.,Ltd. (4577.T) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 3600000000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 4958000000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 5123000000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.